Description : Phosphoinositide cascade is activated on binding of catecholamines to (A) α1-Adrenergic receptors (B) α2-Adrenergic receptors (C) β1-Adrenergic receptors (D) β2-Adrenergic receptors
Last Answer : Answer : A
Description : Agonistic action on which of the following adrenergic receptors located on ciliary epithelial cells reduces aqueous secretion: A. β1 receptor B. β2 receptor C. α1 receptor D. α2 receptor
Last Answer : D. α2 receptor
Description : The following sympathomimetic amine has agonistic action on α1 + α2 + β1 + β3 adrenoceptors, but not on β2 receptors: A. Adrenaline B. Noradrenaline C. Isoprenaline D. Phenylephrine
Last Answer : B. Noradrenaline
Description : Dopaminergic D1 and D2 as well as adrenergic α and β1, but not β2 receptors are activated by: A. Dopamine B. Dobutamine C. Methoxamine D. Phenylephrine
Last Answer : A. Dopamine
Description : Which of the following is not the basis for subclassifying β adrenergic receptors into β1 and β2 : A. Selectivity of agonists B. Selectivity of antagonists C. Transducer pathway of response effectuation D. Organ selective location
Last Answer : C. Transducer pathway of response effectuation
Description : The primary reason for preferring phentolamine as the α adrenergic blocker for performing diagnostic test for pheochromocytoma is: A. It produces rapid and short lasting α-adrenergic blockade B. It equally ... It is the most potent α blocker D. It has no additional β adrenergic blocking property
Last Answer : A. It produces rapid and short lasting α-adrenergic blockade
Description : The bladder trigone and prostatic muscles are relaxed by: A. Adrenergic α1 agonists B. Adrenergic α1 antagonists C. Adrenergic α2 agonists D. Adrenergic α2 antagonists
Last Answer : B. Adrenergic α1 antagonists
Description : A specific cortisol binding protein, transcortin is a (A) Albumin (B) α1-Globulin (C) α2-Globulin (D) β-Globulin
Last Answer : Answer : C
Description : In Thymol turbidity test the protein involved is mainly (A) Albumin (B) α1-Globulin (C) α2-Globulin (D) β Globulin
Last Answer : Answer : D
Description : Rapid intravenous injection of clonidine causes rise in BP due to: A. Stimulation of vasomotor centre B. Release of noradrenaline from adrenergic nerve endings C. Agonistic action on vascular α2 adrenergic receptors D. Cardiac stimulation
Last Answer : C. Agonistic action on vascular α2 adrenergic receptors
Description : In the blood the vitamin esters are attached to (A) α1-lipoproteins (B) α2-lipoproteins (C) β-lipoproteins (D) γ-lipoproteins
Description : Retinol is transported to the blood as retinol attached to (A) α1-globulin (B) α2-globulin (C) β-globulin (D) γ-globulin
Description : Ceruloplasmin is (A) α1-globulin (B) α2-globulin (C) β-globulin (D) None of these
Description : The equivalent production rules corresponding to the production rules S→Sα1|Sα2|β1|β2 is (A) S→β1 | β2, A→α1A | α2A | λ (B) S→β1 | β2 | β1A | β2A, A→α1A | α2A (C) S→β1 | β2, A→α1A | α2A (D) S→β1 | β2 | β1A | β2A, A→α1A | α2A | λ
Last Answer : (D) S→β1 | β2 | β1A | β2A, A→α1A | α2A | λ
Description : Labetalol differs from propranolol in that: A. It has additional α1 blocking property B. It is a selective β1 blocker C. It does not undergo first pass metabolism D. All of the above
Last Answer : A. It has additional α1 blocking property
Description : Adrenergic β2 agonists produce muscle tremor by: A. Facilitating neuromuscular transmission B. Incomplete fusion of contractile response of individual fibres C. Enhanced firing of muscle spindles D. Both (b) and (c) are correct
Last Answer : D. Both (b) and (c) are correct
Description : Beta adrenergic blockers lower intraocular tension by: A. Down regulating adenylyl cyclase in ciliary body through reduced activation of β2 adrenoceptors B. Constricting ciliary blood vessels ... action on trabecular meshwork D. Reducing aqueous formation unrelated to beta adrenoceptor mediation
Last Answer : A. Down regulating adenylyl cyclase in ciliary body through reduced activation of β2 adrenoceptors
Description : Labetalol has: A. More potent β adrenergic blocking than α blocking activity B. More potent α adrenergic blocking than β blocking activity C. Equal α and β adrenergic blocking activity D. β1 agonistic activity in addition to α and β adrenergic blockade
Last Answer : A. More potent β adrenergic blocking than α blocking activity
Description : Adrenergic β1 selective blockers offer the following advantages except: A. Lower propensity to cause bronchospasm B. Less prone to produce cold hands and feet as side effect C. Withdrawal is less likely to exacerbate angina pectoris D. Less liable to impair exercise capacity
Last Answer : C. Withdrawal is less likely to exacerbate angina pectoris
Description : The β adrenergic blocker having β1 selectivity, intrinsic sympathomimetic activity and membrane stabilizing property is: A. Carvedilol B. Atenolol C. Acebutolol D. Metoprolol
Last Answer : C. Acebutolol
Description : Choose the drug which is used as a short-term inotropic in severe congestive heart failure and has selective adrenergic β1 agonistic activity but no dopaminergic agonistic activity: A. Dopamine B. Dobutamine C. Amrinone D. Salmeterol
Last Answer : B. Dobutamine
Description : Low dose therapy with the following category of antihypertensive drugs has been found to be more advantageous in the long-term than high dose therapy with the same drugs: A. β adrenergic blockers B. α1 adrenergic blockers C. Central sympatholytics D. Diuretics
Last Answer : D. Diuretics
Description : Select the β-adrenergic blocker that has additional α1 blocking, vasodilator and antioxidant properties: A. Carvedilol B. Celiprolol C. Acebutolol D. Metoprolol
Last Answer : A. Carvedilol
Description : The following is a skeletal muscle relaxant that acts as a central α2 adrenergic agonist: A. Tizanidine B. Brimonidine C. Chlormezanone D. Quinine
Last Answer : A. Tizanidine
Description : Adrenergic neurone blocking drugs: A. Block the action of adrenaline on neuronal α2 adrenoceptors B. Block both α and β adrenoceptor mediated effects of injected adrenaline C. Do not block any effect of injected adrenaline D. Do not block the effects of sympathetic nerve
Last Answer : C. Do not block any effect of injected adrenaline
Description : The α2 adrenoceptors are: A. Located exclusively on the adrenergic nerve endings B. Prejunctional, postjunctional as well as extrajunctional in location C. Selectively activated by phenylephrine D. Selectively blocked by clonidine
Last Answer : B. Prejunctional, postjunctional as well as extrajunctional in location
Description : The following is an α2 adrenergic agonist used as eyedrops to lower intraocular pressure: A. Brinzolamide B. Bambuterol C. Brimonidine D. Latanoprost
Last Answer : C. Brimonidine
Description : Currently, the first choice drug for open angle glaucoma is: A. Miotic eye drops B. Ocular α2 adrenergic agonists C. Ocular prostaglandin analogues D. Ocular β adrenergic blockers
Last Answer : D. Ocular β adrenergic blockers
Description : Adrenergic neurone blocking drugs: A. Block the action of adrenaline on neuronal α2 adrenoceptors B. Block both α and β adrenoceptor mediated effects of injected adrenaline C. Do not block any effect of injected adrenaline D. Do not block the effects of sympathetic nerve stimulation
Description : Binding of catecholamines to α2− adrenergic receptors (A) Increases the intracellular concentration of cAMP (B) Increases the intracellular concentration of cGMP (C) Decreases the intracellular concentration of cAMP (D) Decreases the intracellular concentration of cGMP
Description : Norepinephrine binds mainly to (A) α-Adrenergic receptors (B) β-Adrenergic receptrors (C) Muscarinic receptors (D) Nicotinic receptors
Description : Tyrosine kinase activity is present in (A) α-Adrenergic receptors (B) β-Adrenergic receptors (C) Cholinergic receptors (D) Insulin receptors
Description : Binding of thyroxine to its receptors (A) Activates Adenylate cyclase (B) Activates guanylate cyclase (C) Activates a stimulatory G-protein (D) Increases transcription
Description : Retinol and retinol –binding protein (RBP) bound with this protein: (A) Albumin (B) Prealbumin (C) α2-globulin (D) β-globulin
Last Answer : Answer : B
Description : Retinol is transported in blood bound to (A) Aporetinol binding protein (B) α2-Globulin (C) β-Globulin (D) Albumin
Description : Dobutamine differs from dopamine in that (a) It does not activate peripheral dopaminergic receptors (b) It does not activate adrenergic ß receptors (c) It causes pronounced tachycardia (d) It has good blood-brain barrier penetrability
Last Answer : Ans: A
Description : a2–adrenergic receptors are associated with following except (a) Increase in phospholipase C activity (b) Increase in potassium channel conductance (c) Decrease in calcium channel conductance (d) Increase in adenylyl cyclase activity
Last Answer : Ans: D
Description : Which of the following receptors does not span the cell membrane 7 times a. β-Adrenergic receptor b. Rhodopsin c. 5-HTic receptor d. Mineralocorticoid receptor
Last Answer : Mineralocorticoid receptor
Description : Improvement of memory in Alzheimer's disease is brought about by drugs which increase transmission in (A) cholinergic receptors (B) dopaminergic receptors (C) GABAergic receptors (D) adrenergic receptors
Last Answer : (A) cholinergic receptors
Description : Methyldopa lowers BP by: A. Inhibiting dopa decarboxylase in adrenergic nerve endings B. Generating α-methyl noradrenaline in brain which reduces sympathetic tone C. Generating α-methyl ... as a false transmitter in peripheral adrenergic nerve endings D. Activating vascular dopamine receptors
Last Answer : B. Generating α-methyl noradrenaline in brain which reduces sympathetic tone
Description : Dobutamine differs from dopamine in that: A. It does not activate peripheral dopaminergic receptors B. It does not activate adrenergic β receptors C. It causes pronounced tachycardia D. It has good blood-brain barrier penetrability
Last Answer : A. It does not activate peripheral dopaminergic receptors
Description : Ergotamine relieves migraine by: A. Blocking vascular α adrenergic receptors B. Blocking vascular 5-HT2 receptors C. Dilating cranial arterio-venous shunt channels D. Constricting cranial vessels and reducing perivascular neurogenic inflammation
Last Answer : D. Constricting cranial vessels and reducing perivascular neurogenic inflammation